Director, Search & Evaluation Early TA Lead

Two Directors of Search & Evaluation to lead strategic sourcing and evaluation of external innovation opportunities in Hematology, and Cardiovascular/Renal therapeutic areas. Embedded within each Therapeutic Area Leadership Team (TALT), these leaders will identify and advance high-potential assets from preclinical through Phase 1 clinical stages, shape early partnering strategies, and drive transactions in collaboration with Business Development

• Serve as the senior Early S&E leader within the TALT, influencing therapeutic strategy and ensuring external innovation priorities are integrated into portfolio planning.
• Lead proactive sourcing and scouting efforts for preclinical and Phase 1 assets, building a robust pipeline of opportunities aligned with TA strategy.
• Co-lead internal meetings (with Late Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations
• Develop and execute early partnering strategies, including onboarding approaches and competitive positioning for priority assets.
• Drive cross-functional due diligence for each opportunity, coordinating scientific, clinical, regulatory, and commercial assessments to inform governance decisions.
• Transaction Execution: Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution
• Represent the TA externally, leading sourcing activities at specialized conferences and cultivating relationships with biotech, academia, and investment communities.

Qualifications & Experience Requirements

• Significant tenure in biopharma with significant experience in external innovation, search & evaluation, or business development.
• Advanced degree required (PhD, MD, or equivalent).
• Must have deep scientific expertise in Hematology or Cardiovascular/Renal therapeutic areas.
• Proven track record of leading due diligence and closing early-stage deals.
• Strong network within biotech, academia, and pharma BD organizations.